Equities researchers at BTIG Research began coverage on shares of Humacyte (NASDAQ:HUMA) in a report released on Wednesday, Price Targets.com reports. The firm set a “buy” rating and a $19.00 price target on the stock. BTIG Research’s price target points to a potential upside of 51.39% from the company’s previous close.
Separately, Piper Sandler assumed coverage on Humacyte in a report on Thursday, September 16th. They issued an “overweight” rating and a $17.00 target price for the company.
HUMA opened at $12.55 on Wednesday. Humacyte has a twelve month low of $9.12 and a twelve month high of $17.45.
Alpha Healthcare Acquisition Corp. is a blank check company. It formed for the purpose of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Alpha Healthcare Acquisition Corp. is based in New York.
Featured Article: What is a blue-chip stock?
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.